???Cancer treatment continues to move in the direction of tailoring therapies to meet the needs of the specific types of cancers and patients,??? said Richard Gaynor, M.D., vice president, cancer research and global oncology platform leader for Lilly. ???Our goal is to further explore the biologic rationale for this observation in non-squamous histology and work toward developing a biomarker appro